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Abstract
Background: Metastatic pancreatic cancer has a dismal prognosis, with a mean six-month progression-free survival
of approximately 50% and a median survival of about 11 months. Despite intensive research, only slight improvements
of clinical outcome could be achieved over the last decades. Hence, new and innovative therapeutic strategies are
urgently required. ParvOryx is a drug product containing native parvovirus H-1 (H-1PV). Since H-1PV was shown
to exert pronounced anti-neoplastic effects in pre-clinical models of pancreatic cancer, the drug appears to be a
promising candidate for treatment of this malignancy.
Methods: ParvOryx02 is a non-controlled, single arm, open label, dose-escalating, single center trial. In total
seven patients with pancreatic cancer showing at least one hepatic metastasis are to be treated with escalating
doses of ParvOryx according to the following schedule: i) 40% of the total dose infused intravenously in equal
fractions on four consecutive days, ii) 60% of the total dose injected on a single occasion directly into the hepatic
metastasis at varying intervals after intravenous infusions. The main eligibility criteria are: age ≥ 18 years, disease
progression despite first-line chemotherapy, and at least one hepatic metastasis. Since it is the second trial within
the drug development program, the study primarily explores safety and tolerability after further dose escalation
of ParvOryx. The secondary objectives are related to the evaluation of certain aspects of anti-tumor activity and
clinical efficacy of the drug.
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Discussion: This trial strongly contributes to the clinical development program of ParvOryx. The individual hazards for
patients included in the current study and the environmental risks are addressed and counteracted adequately. Besides
information on safety and tolerability of the treatment after further dose escalation, thorough evaluations of
pharmacokinetics and intratumoral spread as well as proof-of-concept (PoC) in pancreatic cancer will be gained in the
course of the trial.
Trial registration: ClinicalTrials.gov-ID: NCT02653313, Registration date: Dec. 4th, 2015.
Keywords: H-1 parvovirus, Parvovirus, Oncolytic virotherapy, Pancreatic cancer, Pancreatic ductal adenocarcinoma,
PDAC, Clinical protocol
Background
According to epidemiological estimations for 40 European
countries the overall incidence of pancreatic cancer in the
year 2012 amounted to approximately 10.5 cases per
100,000 inhabitants [1]. The figures for mortality were
only slightly lower with 10.1 cases per 100,000, indicating
the limited treatment options for this disease [1, 2]. Unlike
in other neoplasms, the apparent mortality from pancre-
atic cancer has increased gradually in the past decades
and was approximately 20 to 30% higher in 2014 than in
1970. This is probably due to an improvement of
diagnostic procedures with a parallel increase in the
number of properly documented disease cases. Never-
theless, pancreatic cancer is the only major cancer
showing nearly no improvement of therapeutic outcome
over the last decades [1–3].
Currently, there are no modalities for early diagnosis
or screening for pancreatic cancer so that the disease is
typically discovered only at advanced stages. Based on
the analysis of the US National Cancer Database
(NCDB) performed by the American Joint Committee
on Cancer (AJCC) for the period between 1992 and
1998, the following relative distribution of disease stages
at the time of the initial diagnosis can be assumed: stage
I 9.8, stage II 21.9, stage III: 13.0, and stage IV 55.2%.
The corresponding 5-year survival rates are: 25.3, 11.6,
2.7, and 0.7%, respectively [4]. The locally advanced
(stage III) and metastatic disease (stage IV) are primarily
not eligible for surgical intervention and therefore asso-
ciated with poor prognosis. The current standard of care
for these tumor stages relies upon different chemothera-
peutic regimens.
Based on the results of a randomized, controlled
clinical trial comparing the therapeutic efficacy of a
combination of oxaliplatin, leucovorin, irinotecan, and
5-FU (FOLFIRINOX) to monotherapy with gemcita-
bine, FOLFIRINOX has been established as the first-
line therapy in patients with inoperable pancreatic
cancer who are in good physical condition([5]). An-
other phase III randomized, controlled clinical trial
including 861 patients compared the clinical outcome
after treatment with a combination of nab-paclitaxel and
gemcitabine to gemcitabine alone [6]. As the drug com-
bination showed significant increase in overall survival
with acceptable toxicity, it was approved for the first-line
treatment of inoperable disease by the US Food and
Drug Administration (FDA) [7]. However, neither
FOLFIRINOX nor the combination of nab-paclitaxel
and gemcitabine bring about any relevant advantage
in terms of long-term clinical outcome [5, 6].
Trial rationale/justification
As briefly outlined above, despite intense efforts to improve
treatment, the prognosis for pancreatic cancer patients is
still disappointing. Therefore, all agents showing anti-
tumor effects with an acceptable safety profile should
undergo rapid clinical development to assess their thera-
peutic potential.
ParvOryx is a drug that contains parvovirus H-1
(H-1PV) as active substance. H-1PV is a small, single-
stranded rodent DNA virus. The natural host is rat, but like
other related parvoviruses, H-1PV is able to infect and rep-
licate in cells of various other species including humans.
Parvoviruses exert cytopathic effects mainly in neoplastic
cells: they preferentially kill in-vitro-transformed and
tumor-derived human and rodent cell lines, with limited-
to-no cytocidal action in non-transformed cells [8].
Moreover, these viruses have been shown to have onco-
suppressive properties, inhibiting the formation of
spontaneous as well as chemically or virally induced
tumors in laboratory animals [8, 9]. Furthermore, im-
plants of tumor cells, including human neoplastic cells,
were shown to be targets for parvoviral anti-cancer
activity (oncolysis) in recipient animals [8–12]. Parvo-
viral cytotoxicity seems to be attributed to the viral
nonstructural protein NS-1 [13].
H-1PV showed efficacy in preclinical, in-vitro models
of pancreatic cancer. All investigated human pancreatic
cancer cell lines, both of primary tumor and of meta-
static origin, were susceptible to the stand-alone treat-
ment with H-1PV, although to a varying extent [14, 15].
Synergistic increase of efficacy could be achieved by
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combination with valproic acid (VPA), a histone deace-
tylase inhibitor (HDACI) [14]. Moreover, based on the
results from investigations on cellular pathways affected
by H-1PV as well as by gemcitabine, synergistic effects
of concomitant treatment with both agents can be
anticipated [15]. Consecutive preclinical in-vivo investi-
gations in animal models of pancreatic cancer carried
out in mice and rats showed promising effects of H-
1PV in the dose range between 1E09 and 2.5E09 plaque
forming units (pfu). The anti-tumor effects were dose-
dependent and the viral proteins were selectively
expressed in the tumor as opposed to normal tissues.
H-1PV virotherapy in an orthotopic pancreatic carcin-
oma model led to a significant delay in tumor growth
and prolongation of survival, with 20% of the treated
animals remaining disease-free for 16 weeks [15].
Importantly, in some cases, complete remission of pre-
existing tumors was observed. Moreover, inoculation of
the primary tumor with H-1PV at early stages of tumor
development resulted in almost 50% suppression of
distant metastases involving the visceral lymph nodes
of the upper abdominal cavity and liver [15]. Also in
animal models, the co-administration of VPA increased the
potency of H-1PV, allowing a dose reduction by one power
of ten down to 2.5E08 pfu without loss of efficacy [14].
Based on the findings described above, ParvOryx can
reasonably be assumed to show efficacy against pancre-
atic cancer in humans. Ideally, the drug would not only
be directly cytotoxic to the neoplastic cells but also in-
duce anti-cancer vaccination by destruction of cancer
cells and activation of the adaptive immune system.
Based on the preclinical investigations synergistic effects
with gemcitabine, a drug commonly used for treatment
of pancreatic cancer, can be assumed. Thus, there is a
strong rationale for treating patients suffering from pan-




The trial aims at investigation of safety and tolerability,
virus distribution and shedding as well as at evaluation of
anti-tumor activity and clinical efficacy after multiple
intravenous and a single intrametastatic administration of
ParvOryx to patients suffering from pancreatic cancer.
Objectives
Primary objectives
The primary objectives of the trial are related to the
safety and tolerability of the Investigational Medicinal
Product (IMP):
 Safety and tolerability assessed on the basis of
physical examinations, chosen laboratory
parameters, 12-lead electrocardiogram (ECGs),
adverse events (AEs), and serious adverse events
(SAEs),
 Assessment of humoral immune response to
H-1PV after intravenous infusions and intrametastatic
injection (detection of anti-drug-antibodies (ADA)),
 Investigation of the kinetics of H-1PV genomes in
blood following intravenous and intrametastatic
administration of the IMP by means of quantitative
real-time polymerase chain reaction (qPCR),
 Investigation of virus shedding in faeces, urine, and
saliva following intravenous and intrametastatic
administration of the IMP.
Secondary objectives
The secondary objectives of the study are related to the
anti-tumor activity and clinical efficacy of the IMP:
 Investigation of anti-tumor effects of ParvOryx by
means of the following histo-immuno-pathological
findings: i) extent of metastatis necrosis, proliferation
rate and other pathological characteristics, ii) density
of tumor-infiltrating immune cells,
 Quantity of cytokines and chemokines in tumor
tissue,
 Investigation of viral replication in the tumor tissue
by means of NS-1 detection in the tumor material,
 Investigation of the cellular immune response
against viral proteins and tumor antigens by means
of enzyme-linked immunospot assay (ELISPOT) and
fluorescence-activated cell sorting (FACS),
 Progression-free survival (PFS) up to 6 months after
the first administration of the IMP (determined by
RECIST criteria),
 Morphological changes of the liver metastasis
assessed by ultrasonography,
 Overall survival (OS) up to 6 months after the first
administration of the IMP,
 Course of the tumor marker carbohydrate antigen
19-9 (CA 19-9) up to 6 months after the first
administration of the IMP.
Design
ParvOryx02 is a non-controlled, single arm, open label,
dose-escalating, single center trial.
Due to an exploratory approach with regard to safety
and tolerability of the IMP, no positive control is used.
In face of the small size of the trial population and the
intensity of collecting the biological samples, including
multiple liver biopsies, no negative control (placebo) was
implemented.
In a foregoing, first-in-man trial, referred to as
ParvOryx01, comprehensive information on safety and
tolerability of the IMP up to the total dose of 5E09 pfu
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administered by systemic (intravenous) as well as by
local (intratumoral and intracerebral) route was obtained.
Since the current trial includes further dose escalation up
to the total dose of 1E10 pfu, a sequential design, includ-
ing intervals of at least 28 days between treatments of
consecutive subjects, is employed.
Due to the complex handling and administration of
the IMP this trial is being performed in a single center
with a sound experience in clinical research as well as in
clinical management of patients with pancreatic cancer.
Eligibility
Histologically confirmed pancreatic ductal adenocarcin-
oma with at least one hepatic metastasis is a prerequisite
for inclusion in this trial. Moreover, patients have to fulfill
the following main inclusion criteria: i) at least 18 years of
age, ii) disease progression despite first-line therapy, iii)
ECOG performance scale 0 or 1, iv) adequate main organ
function, including normal thyroid function, v) negative
beta-HCG-test and willingness to abide by the rules of
adequate contraception.
Main criteria for exclusion of patients are: i) eligibility
for surgery, ii) symptomatic cerebral, pulmonary, osseous
metastases and/or peritoneal carcinomatosis, (iii) liver cir-
rhosis, previous splenectomy and/or severe respiratory
impairment, (iv) chemo- and/or radiotherapy within 2 and
6 weeks prior to trial inclusion, respectively, (v) known al-
lergy to iodinated contrast media, (vi) presumed contact
to pregnant women and/or infants within 2 months after
the first administration of the IMP.
Sample size
As no confirmatory hypothesis tests are performed in this
trial, the choice of sample size was not based on formal
sample size calculation but on the following pragmatic
considerations. The trial aims at evaluating safety and
tolerability as well as proof-of-concept (PoC) regarding
efficacy of ParvOryx in the treatment of pancreatic cancer.
The number of seven subjects is assumed to be adequate
to gain information on safety and tolerability of ParvOryx
at the scheduled dose levels as required for continuation
of the clinical drug development. Moreover, since PoC is
mainly related to pathological and immunological parame-
ters, the size of the trial population seems to be sufficient.
Course of the trial
A schematic overview of the trial is given in Fig. 1. For
each individual subject, the trial consists of three phases,
i.e. screening, treatment (including observation until
study Day 28) and follow-up phase between study Day
28 and 6 months:
 Screening
Screening of patients, aiming at assessment of their
eligibility for the trial and collection of the baseline
parameters, must be carried out within 2 weeks
prior to the study inclusion. Potentially eligible
patients are provided with comprehensive written
and verbal information. Procedures that are carried
out during the screening include:
Written informed consent, demography and medical
history, concomitant medication, physical
examination, vital signs and 12-lead ECG, clinical
chemistry, hematology and coagulation, CA19-9,
ELISPOT and FACS, H-1PV-specific antibodies,
serology of human immunodeficiency virus (HIV),
hepatitis B virus (HBV) and hepatitis C virus (HCV),
pregnancy test, thoracic computed tomography (CT)
and abdominal magnetic resonance imaging (MRI),
abdominal ultrasonography.
At the end of the screening phase the inclusion and
exclusion criteria will be reviewed and the final
Fig. 1 General overview of the course of the trial. The trial consists of three phases: Screening, aiming at verification of patients’ eligibility for the
trial; Treatment, in which the IMP is administered and the chosen parameters on safety, tolerability, distribution and biological activity of ParvOryx
are investigated; Follow-up, aiming at the long-term assessment of safety, tolerability, biological activity and clinical efficacy of ParvOryx. Abbreviations:
i.m.: intrametastatic, i.v.: intravenous, Sub: subjects
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judgment on the subject’s eligibility will be made. If
eligible, the subject will enter the treatment phase
and receive the study-specific intervention.
 Treatment (main intervention)
The IMP in this trial is ParvOryx, i.e. a GMP-grade
preparation of H-1PV. The administration of the
IMP is carried out as follows: i) 40% of the total
dose, divided into four equal fractions (10% of the
total dose each) infused intravenously (i.v.) over 2 h
on four consecutive days, ii) 60% of the total dose
injected on a single occasion directly into the hepatic
metastasis under ultrasound guidance. The timing of
intrametastatic injection differs between the trial
subjects. The injection is to be performed either 6 or
9 or 13 days after the first i.v. administration of the
IMP (see Fig. 1). The total doses of ParvOryx are:
1E09 pfu in the first subject, 5E09 pfu in three
further subjects and 1E10 pfu in the last three
subjects (see Table 1). The dose escalation and
maintenance at the given dose level is only allowed
if ParvOryx proved safe and well-tolerated in the
previously treated subjects.
The different time points for the intrametastatic
injection were chosen to explore the most
appropriate schedule for boosting the anticipated
anti-tumor immune reaction. Furthermore, the tissue
samples taken in parallel to the intrametastatic
treatment will allow for assessment of
pharmacokinetics and pharmacodynamics at the
respective time points.
There are two chemotherapeutics defined as
non-investigational medicinal products (NIMP) in
this trial: i) Gemcitabine, administered at the dose
of 1000 mg/m2 of body surface area (BSA) on
days 1, 8 and 15 of each 28-day cycle. The
administration (cycle 1, day 1) is to be commenced
27 days after the first intravenous administration of
ParvOryx, ii) Nab-paclitaxel, administered at the dose
of 125 mg/m2 of BSA, given on days 1, 8 and 15 of
each 28-day cycle, immediately prior to gemcitabine.
Nab-paclitaxel is to be introduced only in case of
disease progression despite previous treatment with
ParvOryx and gemcitabine. Nab-paclitaxel has
emerged as a second-line treatment option in PDAC
after FOLFIRINOX failure [16]. Mechanistically,
preclinical data suggest that nab-paclitaxel increases
gemcitabine levels by decreasing intratumoral cytidine
deaminase activity [17]. In absence of preclinical
data of combining ParvOryx, gemcitabine and
nab-paclitaxel, a triple therapy was not feasible
within this trial. Nevertheless, this treatment
option should be made available to patients with
disease progression.
Although the primary objective of this trial refers to
the safety and tolerability of ParvOryx, the
investigations related to the local anti-tumor activity
and to the pharmacokinetics (PK) of H-1PV
genomes are of substantial importance. In order to
detect possible time-dependent differences, study
days appointed for biopsies and PK sampling differ
interindividually (see Fig. 2). Likewise, the thorough
blood PK evaluations (PK profiles) are scheduled for
different study days, i.e. they are performed either
on the last day of i.v. administration (3 subjects) or
on the day of intrametastatic administration (the
remaining four subjects) of ParvOryx. In either case
the timing of blood collection is as follows: The first
sample is taken prior to the dosing of the IMP, the
second sample up to 10 min after the end of the
administration procedure, i.e. either at the
end-of-infusion or after intrametastatic injection is
completed; further samples are obtained 0.5, 1, 2, 4,
7 and 22 h thereafter. Three biopsies per subject are
to be collected: i) prior to the overall first
administration of the IMP, ii) 6, 9, or 13 days after
the first i.v. administration of ParvOryx, directly
prior to the intrametastatic administration, iii) either
Table 1 Dosing of ParvOryx in the current trial
Total dose Study Time Individual dose and route of administration Duration
Dose level 1 (1 subject)
1E09 pfu Day 1–4 1E08 pfu, intravenous infusion 2 h
Day 7 6E08 pfu, intrametastatic injection As slowly as feasible
Dose level 2 (3 subjects)
5E09 pfu Day 1–4 5E08 pfu, intravenous infusion 2 h
Day 7 or 10 or 14 3E09 pfu, intrametastatic injection As slowly as feasible
Dose level 3 (3 subjects)
1E10 pfu Day 1–4 1E09 pfu, intravenous infusion 2 h
Day 7 or 10 or 14 6E09 pfu, intrametastatic injection As slowly as feasible
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one or 2 months after the first i.v. administration of
ParvOryx. Since cycle 1 of gemcitabine begins on
day 27, effects of chemotherapy will be accounted
for when interpreting biopsies taken 2 months after
i.v. ParvOryx.
 Follow-up
During the follow-up phase, which extends up to
6 months after the first administration of the IMP,
delayed and/or long-term effects of ParvOryx are
evaluated. If no complications occur, the subjects are
to attend the study visits at months 2, 4 and 6. At
each visit safety, tolerability and clinical efficacy will
be assessed by the parameters described above.
 Trial schedule and duration
ParvOryx02 is the overall second clinical trial with
the IMP ParvOryx. In this trial further dose
escalation is planned. Since the starting dose level
equals to the concluding dose level of the previous
trial (ParvOryx01), a sequential escalation design is
used. The subsequent patient may only receive the
first dose of ParvOryx if the treatment proved safe
and well-tolerated in the previous subject, i.e. if none
of the following pre-defined events occurred up to
27 days after the first i.v. administration: i) elevation
of alanine aminotransferase (ALAT), aspartate
aminotransferase (ASAT), alkaline phosphatase (AP),
bilirubin or c-reactive protein (CRP) > 3 times the
baseline ii) neutrophil count <1.0 × 1E09/L or
>12E09/L, iii) hemoglobin <7.5 g/L, iv) platelet
count <5E10/L, v) INR > 2.5, aPTT >50 s., vi)
occurrence of neurological symptoms with no other
explanation than the administration of the IMP, vii)
occurrence of thromboembolic event(s), vii) serious
adverse events (SAE(s)) classified as at least ‘possibly’
related to the IMP viii) deteriorations in medical
monitoring parameters (laboratory values, ECG,
etc.), classified as at least ‘possibly’ related to the
IMP and requiring countermeasures to avert
conditions fulfilling at least one of the
‘seriousness’-criteria, ix) medical necessity to interrupt
or to prematurely terminate the scheduled treatment.
If any of the before mentioned events occur, an
independent data safety monitoring board (DSMB)
will be provided with all required data and
consulted regarding the trial continuation and/or
implementation of any modifications.
The overall duration of the clinical trial, including
completion of all follow-up visits related to the
efficacy of the IMP in all subjects, is scheduled to
last approximately 12 months.
Specific hygienic measures
ParvOryx contains the active, replication-competent virus.
Therefore, environmental safety has to be considered as
an important factor in the context of administering
ParvOryx.
Based on the findings from the previous clinical trial,
the risk of virus transmission from study patients to other
persons is very low even after the planned dose escalation,
if the general hygienic measures are observed. Thus, there
is no need for isolation of the patients treated with
Fig. 2 Schedule of the main trial-specific interventions. In order to account for potential time-dependent effects, the trial-specific interventions
are to be carried out at different time points. Abbreviations: BPS: biopsy of liver metastasis, LA: local (intrametastatic) administration of ParvOryx,
PK: thorough pharmacokinetic investigations, Sub: subject
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ParvOryx. However, to discover and appropriately meet
the very unlike case of uncontrolled viral replication after
administration of ParvOryx, certain measures have been
implemented. The in-patient stay is to be continued until
first occurrence of H-1PV-specific antibodies in serum or
until all shedding samples (feces, urine, and saliva) are
tested negative for H-1PV genomes. During each follow-
up visit the presence of specific antibodies will be deter-
mined. If the antibodies fall below the detection limit, the
subject has to be re-admitted to the trial unit and the
extent of virus shedding is to be determined. If no viral
genomes are shed in any matrix, no further measures are
required and the subject may be discharged. Otherwise
the subject remains in-patient until re-occurrence of H-
1PV-specific antibodies or until all shedding samples are
tested negative for viral genomes.
The only a-priori planned safety measure related to
environmental safety is that subjects should entirely
avoid contact with pregnant women and infants up to 2
months after the first administration of ParvOryx.
Benefit/risk assessment
As discussed above, no satisfying therapeutic options
exist for treatment of locally advanced and metastatic
pancreatic cancer. The prognosis is dismal with a six-
month progression-free survival of approximately 50%
and a median survival of about 11 months [5].
The first open, non-randomized clinical trial with
ParvOryx, referred to as ParvOryx01, evaluated safety
and tolerability as well as antitumor activity and clinical
efficacy in patients with progressive primary or recurrent
glioblastoma multiforme (GBM). ParvOryx01 was com-
pleted in May 2015 [18]. The investigated doses ranged
between 1E06 and 5E09 pfu. They were administered as
combination of either multiple intravenous infusions or
a single intratumoral injection and multifocal intracere-
bral injections at the end of tumor resection surgery. As
in the current trial, the intravenous dose was divided
into equal fractions which were given on consecutive
days. The interval between the first administration and
surgery with subsequent intracerebral injections of the
drug was 10 days. In general, ParvOryx was safe and
well-tolerated with only one potential serious adverse
reaction observed after a combination of direct glioblast-
oma administration and intracerebral injection at the
end of surgery. The clinical symptoms of the above reac-
tion (mainly hydrocephalus and reduced level of con-
sciousness) were strictly confined to the central nervous
system, i.e. there was no causal link to the systemically
available virus. As the potential underlying pathome-
chanisms remained unclear, the causal relationship to
ParvOryx can neither be confirmed nor excluded. Of
note, no comparable clinical events occurred in any of
the other patients treated by the same route and with
the same dose of ParvOryx. Since neither of the above
routes of administration is used in the current study,
there is no risk of similar adverse reactions.
The single intravenous dose at the initial level equals to
that investigated at the highest level in ParvOryx01. Since
the intravenous administrations are to be performed on
four, instead of five consecutive days, the total intravenous
dose is reduced to 80% of the dose investigated previously.
The starting local, i.e. intrametastatic dose is more than
four times lower than the highest doses injected intratu-
morally and intracerebrally in the foregoing trial. Since the
metastatic/hepatic tissue is presumably far less susceptible
to any kind of injury than the neuronal tissue of the brain,
the chosen approach appears acceptable. Owing to the
overall higher dose range investigated in the current study
as well as to the planned co-treatment with gemcitabine,
the steps of dose-escalation were chosen more conserva-
tively than in the previous trial.
As in the foregoing trial, the treatment of a consecu-
tive subject is only allowed if the treatment was well-
tolerated in the previous subject who, as per protocol,
underwent a close medical monitoring during the treat-
ment and up to 3 weeks thereafter. This sequential
schedule of enrolment minimizes the individual risks for
the included patients.
Although H-1PV is non-pathogenic in man, strong pre-
ventive hygienic measures were implemented in the Par-
vOryx01 study [18]. Amongst others, the investigation of
virus distribution and excretion belonged to the main ob-
jectives of the trial. Considering the fact that no active
virus could ever be detected in any body fluid (faeces,
urine, and saliva) and taking into account the rapid forma-
tion of virus-specific antibodies, the transmission of H-
1PV from the trial patients is considered as highly un-
likely. Thus, it is well justifiable to omit the strict isolation
conditions applied previously and to rely on the general
hygienic standards which are routinely applied at the trial
center. In case of a surface contamination with ParvOryx,
an adequate disinfection is to be carried out. Since H-1PV
was shown to have some embryo- and fetotoxic effects in
rodents [19, 20], the trial subjects are obliged to strictly
avoid contact with pregnant women and newborn infants
for the period of 2 months after beginning of the
treatment with ParvOryx. This is to be considered an
additional safety measure, i.e. there are currently no
indications for a predisposition of pregnant women or
infants for an infection with H-1PV.
The risk of trial-specific procedural complications related
to the intrametastatic administration of ParvOryx, collec-
tion of tissue and blood samples is generally very low.
Taken together, the current protocol of ParvOryx02
trial is well justifiable and may be associated with indi-
vidual benefits for the included patients. Moreover, the
trial will yield important information required for further
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clinical development of ParvOryx, which may have im-
portant implications for the general population of patients
with pancreatic cancer. Taken together, the individual haz-
ards for study subjects and the environmental risks are
well predictable and acceptable.
Statistical analysis
 Analysis variables
Safety and tolerability will be assessed on the basis
of the following parameters:
AEs and SAEs; physical examinations, vital signs,
12-lead ECGs, and chosen laboratory parameters
(clinical chemistry, hematology, coagulation);
viremia and virus shedding (H-1PV genomes (Vg)
and active virus (H-1PV) in body fluids);
virus-specific antibodies.
Efficacy will be assessed on the basis of the
following parameters:
Investigation of the metastatic tissue: findings in
general pathological examination, detection of
H-1PV by FISH and qPCR, assessment of tumor
infiltration with immune cells, determination of
quantity and distribution of cytokines and
chemokines, determination of H-1PV protein
expression (NS-1).
Parameters derived from blood: determination of
absolute and relative abundance of distinct
immune cell subsets as determined by FACS,
investigation of cellular anti-viral and anti-tumor
immunity by ELISPOT.
Clinical Parameters: progression-free survival
(PFS) and overall survival (OS) assessed by
RECIST-criteria.
 Statistical methods
Safety analysis: AEs will be summarized by
MedDRA system organ class and preferred term.
Separate tabulations will be produced for all
treatment-emergent AEs, treatment-related AEs
(those considered by the Investigator as at least
possibly IMP-related), SAEs, and discontinuations
due to AEs. Summary tables and by-patient listings
will be provided for AEs, SAEs, events leading to
discontinuation of treatment, and deaths.
Summary tables and by-patient listings will be
provided for clinical laboratory data and vital signs
data, presented as both actual values and changes
from baseline relative to each on-study evaluation.
Details of any abnormalities will be included in
patient listings.
Efficacy analysis: No confirmatory statistical
analyses will be performed. All recorded variables
(see above) will be analyzed descriptively by
providing by-patient listings as well as calculating
appropriate summary measures as mean, standard
deviation, median, minimum and maximum or
absolute and relative frequencies, respectively. If
appropriate, changes from baseline relative to each
on-study evaluation will be considered. For
time-to-event endpoints (progression-free survival
and overall survival), Kaplan-Meier estimates and
summary measures of the survival function will be
provided. Additionally, analyses will be performed
separately for each particular dose level. The
course of variables over time will be depicted
for the total analysis population as well as for
each subject.
Discussion
Among other emerging biopharmaceuticals, the clinical
use of oncolytic viruses appears to be a promising treat-
ment option for various malignancies. Currently, there is a
range of mainly genetically modified oncolytic viruses
at different stages of clinical development [21–31].
Recently, talimogene laherparepvec (T-vec) received
market authorization by the U.S. Food and Drug Ad-
ministration (FDA) for treatment of melanoma patients
with injectable but non-resectable skin and/or lymph-
atic lesions [32]. In general the tolerability of oncolytic
viruses after systemic and/or local administration is
very good with none or only mild unspecific adverse re-
actions such as fatigue, chills or slight fever. There are
no indications for major organ toxicities, local tissue
damage or induction of adverse immune effects. The
oncolytic viruses are used either as monotherapies or in
combination with established chemotherapeutics and/
or targeted therapies. There are strong indications for
anti-tumor activity and clinical efficacy in connection with
either approach. However, in most cases the optimum
mode of administration, including dosing schedule and
type as well as timing of concomitant treatments still
needs to be specified. Interestingly, concomitant therapy
with oncolytic viruses and checkpoint inhibitors seems
not to influence the safety and tolerability of either treat-
ment [33]. This is of high relevance as the combination
may enhance individual anti-tumor immune responses
with an improvement of clinical outcome.
Recently, ParvOryx was clinically investigated for its
safety and tolerability, anti-tumor activity, immunological
effects, and clinical efficacy in patients with GBM [18]. In
this study the virus was administered intravenously and
into the tumor or in the tumor bed directly after resection.
The drug was safe and well-tolerated and showed a prom-
ising profile of anti-tumor effects and signs of clinical effi-
cacy, i.e. prolonged survival. However, the optimum dose
as well as the most appropriate route and schedule of
administration have to be further investigated. The
current, second trial with ParvOryx, addresses these
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questions. Since the total dose of the drug will be further
escalated, the primary objective is to evaluate the safety
and tolerability of the treatment. At the beginning of the
trial, i.e. at the first level, the total dose of ParvOryx equals
to the highest total dose in the previous trial. Since a rele-
vant part of the total dose has to be administered directly
into the liver metastasis, it is indicated to include one
up-front patient at this level, in order to obtain first
information on the local tolerability of the drug after
direct injection in the liver. Considering the fact that in
the foregoing study the local tolerability in the neuronal
tissue was very good, no safety-related issues are ex-
pected in this context. Since the potential hazards for
the consecutive patients have to be minimized as far as
possible, a sequential, dose escalation design with ex-
tended intervals between enrollment of consecutive
subjects and rather conservative dose escalation steps
was chosen. As in the previous trial, a broad range of
different investigational parameters was implemented.
Apart from extended safety tests, various measurements
enabling insights into the mode and extent of action of
ParvOryx, including local virus availability in the tumor,
triggering of changes at the tissue level and induction
of virus- and PDAC-specific immune responses were
included into the current protocol. Moreover, in order
to account for presumable time-dependency of phar-
macokinetic characteristics, virus disposition in the
tumor tissue and related pharmacodynamics, varying
intervals were intercalated between the intravenous
administrations on the one hand and biopsies of liver
metastases, thorough PK-profiles as well as local ad-
ministrations of ParvOryx on the other hand.
The IMP contains an active, replication-competent
parvovirus H-1PV. Although H-1PV is non-pathogenic in
humans, biosafety is still considered a relevant issue in the
context of administration of ParvOryx. Based on the re-
sults from the previous trial, a transmission of H-1PV
from trial patients to others is highly unlikely, since gen-
eral hygienic measures applicable to the handling of che-
motherapeutics, consumables and nursing of patients are
implemented. Owing to the pre-clinical findings showing
an embryo- and fetotoxicity of H-1PV in rodents, patients’
contact with pregnant women and infants is restricted as
an additional precaution.
In summary, the current trial will provide further
crucial information within the clinical development pro-
gram of ParvOryx. Since there were pronounced anti-
tumor effects of the drug in various preclinical in-vitro
and in-vivo models of pancreatic cancer, the trial will
hopefully bring clinical benefits for study patients and,
in consequence, for the general patient population.
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